ChargePoint’s Verifi Now Supports Biopharma
In an Oct. 10, 2019 press release, ChargePoint Technology announced that its smart monitoring system, Verifi, is now available for the biopharma market.
In an Oct. 10, 2019 press release, ChargePoint Technology announced that its smart monitoring system, Verifi, is now available for the biopharma market. The system is used to monitor the usage data for ChargePoint Technology’s split butterfly valves, ultimately enabling teams to manage maintenance of containment systems and improve safety.
“Verifi gives manufacturers an automatic and reliable method of understanding the health status of their valves so that they can take preventative action. This in turn improves operational performance, productivity, and helps to manage risk,” said Malcolm Cunningham, head of sales EMEIA and LATAM at ChargePoint in the press release. “The response from customers in the pharma market so far has been excellent. Verifi is not only giving the user confidence in the operational performance of SBV technology, but also the safety and quality teams peace of mind.”
Through software advancements of the monitoring system, it is now possible to connect directly onto the ChargePoint AseptiSafe valve unit, which is used to guarantee aseptic processing sterility. Users can then access data from the device or using an online dashboard, allowing for remote data access.
“We are thrilled to be able to service the biopharma market. Given the growth in the biotech sector, extending the application of Verifi to this market is a natural next step for us,” added Cunningham. “By adding unique technologies such as Verifi to our portfolio, we are putting ChargePoint Technology at the forefront of overcoming sterile manufacturing challenges.”
Source: ChargePoint Technology
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
